Nova Eye Medical : Reducing Progression Rate Age-Related Macular Degeneration

onlyuse

ersonalAlphaRET Pty Ltd is a wholly owned subsidiary of Nova Eye Medical Limited (ASX:EYE) and was

stablished to progress the development of 2RT®

AMD is the leading cause of blindness

in the developed world

for people over 50

Reducing Progression Rate of Age-Related Macular Degeneration

December 2021

Disclaimer

onlyThis presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward-looking statements have been made based upon Nova Eye Medical's expectations and beliefs concerning future developments and their potential effect on Nova Eye Medicals (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye

useMedical's control. No assurance is given that future developments will be in accordance with Nova Eye Medical's expectations. Actual results could differ materially from those expected by Nova Eye Medical. This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance

is not necessarily indicative of future results and no person guarantees the ersonalperformance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve

any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.

alpha-ret.com| 2

Age-Related Macular Degeneration

ersonal use only

alpha-ret.com| 3

Reducing Progression Rate of AMD

only		Currently drugs provide	Global spend on
	AMD is the leading	temporary visual recovery	pharmaceuticals
	and stabilization for	US$5.7billion3
	cause of blindness
	patients with "Wet" AMD.	and on vitamins for
	in the developed	There is no treatment for
	eye health
use	world for people	"Dry" AMD and patients
US$2.4billion4
over 501	with intermediate AMD
	take vitamins
ersonal
AMD in its late stage	Expenditure on such	2RT® to be used
	2x per year for
	has two forms:	pharmaceuticals is	treatment of certain
	"Wet" (choroidal	largest spend in the	patients with
	neovascularization)	health care systems	intermediate AMD
	and "Dry" (geographic	of developed	before the patient
	atrophy)	countries2	progresses to late
			stage AMD4

1 "Eyes on the future - A clear look at AMD". Deloitte Access Economics, 2011 , 2. Highlight on Australian Pharmaceutical Benefits scheme year to 30 June 2020 spend on Aflibercept and Ranibizumabs A$577m. Highest on USA	alpha-ret.com| 4
Medicare USA Department of Health, August 2018, $2.2bn. 3. Edison Group report Sept. 2020, 4. Reported in PRN Newswire 5 October 2020, supplements for AMD represents the largest share. 5. Based on a post hoc analysis
LEAD Study

Intermediate Age-Related Macular Degeneration

AMD in its early or intermediate stage is based on the
only
number and size of "drusen".
Drusen are deposits that accumulate between the
pigmented layer of the retina called the retina pigment
endothelium (RPE) and a more outer layer called Bruch's
Membrane ("BM").
use
These deposits inhibit the flow of nutrients to the retina.
The size and extent of drusen in the macular have been
hown to increase the risk of AMD progression.
Intermediate AMD is characterized by large drusen and
medium drusen with pigmentary abnormalities. These
ersonal
p tients are at significant risk for developing AMD both Wet
nd Dry.
Currently there are no treatments for patients with
Intermediate AMD. Vitamins and nutritional
supplements is the recommended standard of care1. 2.
	1. Macular Degeneration Foundation Australia recommendation pamphlet "Nutrition for AMD".
	2. USA National Eye Institute AREDS/AREDS 2 study concluded that supplements reduces the rate of progression from intermediate AMD to advanced AMD by 25%	alpha-ret.com| 5